By Business/Source
Currency:USD
2026/Q1
Stock NameRevenueRatio
Sale of the Company’s Oral and IV TPOXX® as well as research and development services6.24M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States88.75M93.84%
Canada5.82M6.16%